Keros Therapeutics, Inc.
$11.66
▲
2.65%
2026-04-21 07:46:00
www.kerostx.com
NGM: KROS
Explore Keros Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$230.1 M
Current Price
$11.66
52W High / Low
$22.55 / $10.41
Stock P/E
2.64
Book Value
$15.51
Dividend Yield
—
ROCE
21.27%
ROE
19.9%
Face Value
—
EPS
$2.3
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
78
Beta
0.99
Debt / Equity
5.57
Current Ratio
15.45
Quick Ratio
15.45
Forward P/E
-2.22
Price / Sales
1.4
Enterprise Value
$-49.6 M
EV / EBITDA
-0.69
EV / Revenue
-0.2
Rating
None
Target Price
$22.57
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Net margin remains healthy.
- Valuation is not stretched on P/E basis.
Cons
- Operating margin is thin.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Humacyte, Inc. | $0.69 | — | $157.68 M | — | -110.35% | 164.78% | $2.93 / $0.55 | $0.02 |
| 2. | Nurix Therapeutics, Inc. | $17.04 | — | $1.81 B | — | -47.48% | -61.4% | $22.5 / $8.2 | $4.65 |
| 3. | IO Biotech, Inc. | $0.01 | — | $0.55 M | — | -197.41% | -2.4% | $2.79 / $0.01 | $0.01 |
| 4. | Oragenics, Inc. | $0.71 | — | $3.19 M | — | -113.05% | -2.44% | $9.6 / $0.5 | $1.94 |
| 5. | ALX Oncology Holdings Inc. | $1.75 | — | $219.79 M | — | -292.37% | -1.46% | $2.66 / $0.4 | $0.48 |
| 6. | Celularity Inc. | $1.24 | — | $35.47 M | — | -48.8% | -232.51% | $4.35 / $1.01 | $-0.71 |
| 7. | Bio-Techne Corporation | $59.22 | 116.91 | $9.33 B | 0.53% | 10.19% | 3.97% | $72.16 / $46.01 | $12.9 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 0.39 M | 14.26 M | 18.17 M | 211.25 M | 3.04 M |
| Operating Profit | -29.27 M | -15.38 M | -39.82 M | 152.04 M | -52.02 M |
| Net Profit | -23.46 M | -7.28 M | -30.7 M | 148.45 M | -46.03 M |
| EPS in Rs | -1.19 | -0.37 | -1.56 | 7.53 | -2.33 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 244.06 M | 3.55 M | 0.15 M | 0 M |
| Operating Profit | 67.57 M | -209.59 M | -167.54 M | -107.71 M |
| Net Profit | 87.01 M | -187.35 M | -152.99 M | -104.68 M |
| EPS in Rs | 4.41 | -9.5 | -7.76 | -5.31 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 338.02 M | 615.89 M | 370.02 M | 306.78 M |
| Total Liabilities | 34.89 M | 44.33 M | 37.81 M | 29.36 M |
| Equity | 303.13 M | 571.55 M | 332.21 M | 277.42 M |
| Current Assets | 315.43 M | 588.89 M | 347.29 M | 285.77 M |
| Current Liabilities | 20.41 M | 27.45 M | 24.37 M | 16.55 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 107.5 M | -160.87 M | -124.51 M | -70.06 M |
| Investing CF | -1.55 M | -1.93 M | -2.46 M | -1.24 M |
| Financing CF | -378.47 M | 391.82 M | 178.96 M | 120.31 M |
| Free CF | 105.95 M | -162.8 M | -126.97 M | -71.3 M |
| Capex | -1.55 M | -1.93 M | -2.46 M | -1.24 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 2250.99% | — | — | — |
| Earnings Growth % | -22.46% | -46.15% | — | — |
| Profit Margin % | -5277.55% | -101319.21% | — | — |
| Operating Margin % | -5904.08% | -110954.3% | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -5869.46% | -100779.47% | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.